CLR 1404 I-131

Drug Profile

CLR 1404 I-131

Alternative Names: (131)I-CLR1404; 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine; 131I-CLR1404; 131I-NM 404; CLR 131; CLR1404 I-131; HOT; I-131-CLR1404; NM404

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Phospholipids; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 15 Mar 2017 Cellectar plans a phase II trial for Haematological malignancies
  • 08 Mar 2017 Cellectar Biosciences enters into a licensing agreement with the Wisconsin Alumni Research Foundation for intellectual property rights covering the method of use CLR 1404-131 for Multiple myeloma
  • 27 Feb 2017 Interim adverse events, pharmacodynamics and efficacy data from a phase I trial in Multiple myeloma released by Cellectar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top